Background Results from previous studies show that the cognitive ability of off spring might be irreversibly damaged as a result of their mother's mild iodine defi ciency during pregnancy. A reduced intelligence quotient (IQ) score has broad economic and societal cost implications because intelligence aff ects wellbeing, income, and education outcomes. Although pregnancy and lactation lead to increased iodine needs, no UK recommendations for iodine supplementation have been issued to pregnant women. We aimed to investigate the cost-eff ectiveness of iodine supplementation versus no supplementation for pregnant women in a mildly to moderately iodine-defi cient population for which a populationbased iodine supplementation programme-for example, universal salt iodisation-did not exist.
Introduction
Severe iodine defi ciency in pregnancy is linked to impaired neurodevelopment of the unborn child, manifesting in a permanent reduction in intelligence quotient (IQ) and cretinism in some children. 1, 2 A systematic review of iodisation programmes and trials in China reported an 8·7 (95% CI 6·3-11·1) IQ point diff erence in children born to women in severely defi cient regions with and without iodine supplementation during pregnancy and after birth. 2 However, strong evidence exists 1,2 that this cognitive impairment is prevented by iodine supplementation in pregnancy. Although the cognitive eff ects of severe iodine defi ciency in pregnant women are established, the eff ect of mild iodine defi ciency is less clear. 3 In two cohort studies in the UK and Australia, 9- year-old children of women who had a urinary iodine concentration suggestive of mild iodine defi ciency during their pregnancy had reduced education outcomes 4 and decreased IQ scores 5 compared with children of iodine-replete women. By contrast, a large Spanish cohort study, 6 which undertook cognitive assessment of infants at a median age of 16 months, did not report a signifi cant association between iodine supplementation and cognitive outcomes.
The UK is one of a decreasing number of countries that does not have any iodine fortifi cation of food or salt and some of the UK population is now believed to have become mildly iodine defi cient. 7 At present, no national guidance for iodine supplementation has been issued to pregnant women, even though pregnancy and lactation lead to increased iodine requirements. 8, 9 A reduced IQ in infancy has broad future economic societal costs because cognitive development has eff ects on health outcomes, educational attainment, and lifetime earnings. A reduced IQ is associated with an increased rate of mortality, 10 an increased risk of suicide, 11 psychiatric illness, 12, 13 and an increased incidence of heart disease. 14, 15 An increased IQ is postulated to have a positive eff ect on an individual's health-improvement behaviour, 16 and those with increased childhood IQ scores are signifi cantly more likely to have higher educational attainment and earnings by the age of 25 years. 17 Here, we report the results of a model-based economic evaluation using the best available data from the existing published scientifi c literature, a systematic literature search, and expert clinical input. Because of the need for data-supported assumptions to complete the analysis, we used an approach that limited the benefi ts of iodine supplementation and overestimated its potential harms as far as possible. We aimed to use economic evaluation to compare the costs and benefi ts of a strategy of iodine supplementation tablets with a strategy of no iodine supplementation for pregnant women in a mildly to moderately iodine-defi cient population.
Methods

Model structure
We developed a decision tree model in TreeAgePro 2014 (TreeAge Software, Williamstown, MA, USA) to represent two alternative strategies-iodine supplementation versus no iodine supplementation. The model pathways (fi gure) represent the alternative clinical pathways undertaken by pregnant women.
We are interested in the incremental costs and eff ects of giving universal iodine supplementation to pregnant women. The model pathways represent the alternative (simplifi ed) clinical pathways undertaken by pregnant women. Some of the pregnancies will be unsuccessful and we will not realise any IQ gain related benefi ts of iodine supplementation. Successful pregnancies without complications due to iodine supplementation intervention whose mothers were iodine defi cient presupplementation receive IQ gain related benefi ts for their newborn baby. Pregnant women who were iodine suffi cient without supplementation with normal thyroid function receive no IQ gains for their off spring. We have stacked the cards against iodine supplementation being cost eff ective with very conservative assumptions. We assumed that some women suff er adverse thyroid dysfunction as a result of iodine supplementation. An increased incidence of pregnancy losses and complications for each type of thyroid dysfunction is caused by iodine supplementation. Pregnancy complications push up the costs from iodine supplementation. Hypothyroidism and isolated hypothyroxinaemia induced by iodine supplementation are assumed to lose IQ points for the off spring. IQ points were subtracted for the children of mothers with adverse thyroid dysfunction from iodine supplementation who were iodine defi cient presupplementation.
Variables and their respective sources are listed in table 1. Data for the probability of a pregnant woman in the UK being iodine defi cient is based on the only UK data available and refers to a selective cohort of women. 5 The proportion of pregnant women in each iodine status category-mild to moderate (median urinary iodine concentration [UIC] of 50-149 μg/L) and severe (UIC <50 μg/L)-and the subsequent eff ect on a child's IQ were based on a cohort study 5 that examined the association between iodine status during the fi rst trimester of pregnancy and the IQ of their children at age 9 years.
The cost of iodine tablets is based on the cost of local supermarket multivitamin tablets for pregnant women (£3·50 for 30 tablets typically containing 140 μg or 150 μg of iodine). 37 A daily dose of 150 μg of iodine is recommended by the American Thyroid Association 38 and
Research in context
Evidence before this study We searched PubMed, with no restrictions on date or language, with the keywords "iodine", "dietary supplements", "pregnancy", "intelligence", "cognition", "child development", and "costs and cost analysis". We identifi ed no studies reporting the cost-eff ectiveness of iodine supplementation in pregnancy in a mildly iodine-defi cient population. We identifi ed a 2013 systematic review, which focused on mildly to moderately iodine-defi cient populations, which concluded that "the impact of maternal iodine supplementation on newborn neurodevelopment remains uncertain due to lack of appropriate controlled intervention trials". One other systematic review of research in mildly to moderately iodine-defi cient populations from 2009 reported benefi ts of maternal iodine supplementation on maternal thyroid indices, but underlined the need for further data for infant neurodevelopment. In two cohort studies in the UK and Australia, 9-year-old children of women who had a urinary iodine concentration suggestive of mild iodine defi ciency during their pregnancy had reduced educational outcomes and decreased IQ scores compared with children of iodine-replete mothers.
Added value of this study
To our knowledge, this study is the fi rst model of the costeff ectiveness of iodine supplementation in pregnant women in a mildly to moderately iodine-defi cient population. We used an economic model of best available evidence and assumptions that do not favour iodine supplementation and identifi ed that universal iodine supplementation before pregnancy and during pregnancy and lactation increased the child's IQ by 1·22 points, saved the UK NHS £199 and society £4476 per pregnant woman.
Implications of all the available evidence
Available evidence suggests that a policy of iodine supplementation during pregnancy would be benefi cal. Ideally, a randomised controlled trial would be undertaken to confi rm our fi ndings.
the European Thyroid Association 39 for euthyroid pregnant and lactating women. Annual incremental health and services costs and public sector costs, including education by a child's IQ category, are taken from a study 40 that looked at the costs associated with neurological impairment when children were aged 11 years old. The incremental childhood cost of preterm birth and the health-care cost associated with stillbirth are taken from published sources. 41, 42 We discounted costs at the standard annual rate of 3·5% 24 and updated them to 2013 prices using a subset of the Consumer Price Index, covering price infl ation in education, health, and social protection. 43 Public sector costs included in the model consist of health and social services costs, and education costs.
We did an additional systematic search of the scientifi c literature to establish a monetary value for an IQ point to use in the economic evaluation (appendix p 2). To complete the analysis, some pragmatic assumptions were needed and were informed by the scientifi c literature and expert opinion. As far as possible, assumptions were conservative. Our model assumptions are listed in panels 1 and 2.
Analyses
We did two separate analyses. In the fi rst analysis (analysis 1), we used a health service perspective in which direct health service costs are taken into account. In the second analysis (analysis 2), we used a societal perspective that additionally takes into account education costs and the value of an IQ point itself.
For both analyses, we assumed that IQ follows the conventional normal distribution with a mean of 100 and a standard deviation of 15. We used Z tables to calculate the reduction in the proportion of children in the lower IQ categories as a result of iodine supplementation (appendix p 9). The present value health and social services costs for the fi rst 16 years of life are calculated for children with a mild neurodevelopmental impairment (IQ scores of 82-92); this is also calculated for children with a moderate or severe neurodevelopmental disability (IQ scores of ≤81), but with an additional cost of special education. These costs savings are then adjusted for survivors by use of UK life tables. 44 The monetary value of an IQ point (analysis 2 only) was identifi ed by the systematic search done as part of this study (appendix p 2). Analyses 1 and 2 are both presented in terms of their disaggregated cost (in sterling) and outcomes in the form of a cost-consequence analysis, and IQ points gained are reported as natural units.
To investigate the robustness of the base case results, we did a comprehensive sensitivity analysis in which the main motivation was to further disadvantage the eff ect of iodine supplementation in the model and assess the eff ect on the results (appendix p 8). Most of the changes explored, for both analyses 1 and 2, were arbitrary where, for example, any gains as a result of iodine supplementation were halved and any detrimental eff ects as a result of the supplementation were doubled. A probabilistic sensitivity analysis was not appropriate in this case because we were already using estimates for the worst case scenario rather than using central mean estimates. We identifi ed evidence on the benefi ts of iodine supplementation using systematic reviews and from experts on iodine status and supplementation in pregnant women. We identifi ed three cohort studies of iodine status in pregnancy and IQ or cognitive development in infants and children [4] [5] [6] and two trials of iodine supplementation in pregnant women. 45, 46 
Role of the funding source
There was no funding source for this study. All authors made the collective decision to submit for publication.
Results
Our systematic search identifi ed 1361 published articles, of which eight studies [47] [48] [49] [50] [51] [52] [53] [54] passed quality criteria and were assessed to calculate the monetary value of an IQ point (appendix p 4). The quality criteria were as follows: an individual's IQ is used and is not a proxy; variables are clearly specifi ed; IQ measure follows a conventional
Data Sources
Probability of a pregnant woman being iodine defi cient (%) 67% Bath and colleagues 5 ; Vanderpump and colleagues 18 showed a similar proportion of iodine defi ciency in [14] [15] year old girls in the UK normal distribution with a mean of 100 and standard deviation of 15 or suffi cient information is included in the study to allow the IQ measure's distribution to be converted into one (for cross study comparability); and the results reported in currency form have the applicable year stated. Most of the studies valued an IQ point on the basis of its eff ect on an individual's income (appendix p 3). The issue of diff erences in scaling of IQ tests hindered the comparability across studies. The value of an IQ point, derived from the systematic search and applied to the unborn cohort, comes from the lifetime earnings premium of an additional IQ point. This is calculated to be £3297 (study estimates range from £1319 to £11 967; after adjustment with life tables).
With the use of base case assumptions, the results of both analyses show that the iodine supplementation strategy was less costly and more eff ective compared with no supplementation (table 2) . From the UK NHS perspective, where only health-related costs were taken into account (analysis 1), iodine supplementation was cost saving, with an expected positive net present value of £199 per pregnant woman (sensitivity analysis range -£42 to £229) and an increase of an average 1·22 IQ points for the unborn infants. From a societal perspective (analysis 2), iodine supplementation was cost saving with an expected positive net present value of £4476 per pregnant woman (sensitivity analysis range £540 to £4495), and an average increase of 1·22 IQ points for the unborn infants.
For the pregnant women for whom thyroid dysfunction was precipitated by iodine supplementation, an average cost of more than £91 000 each would have to be incurred to negate the overall benefi ts arising from the iodinedefi cient pregnant women without thyroid dysfunction taking iodine supplementation in the model looking at the NHS perspective alone.
The sensitivity analysis supported the cost saving indication of base case results (table 2; appendix p 8). Iodine supplementation remained cost saving in all the sensitivity scenarios undertaken with one exception: in analysis 1 (health service perspective) where we assumed zero IQ gain for children of the previously mild to moderately iodine-defi cient women, the results suggested an additional cost of £42 per pregnant woman for a gain of 0·17 IQ points for their off spring (table 2).
Discussion
To our knowledge, this study is the fi rst to estimate the cost-eff ectiveness of a policy of iodine supplementation during pregnancy and lactation in a population with mild to moderate iodine defi ciency. The analyses showed that iodine supplementation saved money and improved IQ. The results were supported by all the sensitivity analysis scenarios apart from the most extreme scenario, in which supplementation of mildly iodine-defi cient pregnant women did not improve IQ. A key strength of the analysis was the use of very conservative assumptions to limit the benefi ts of iodine supplementation and potentially overestimate adverse outcomes arising from supplementation. In view of the preliminary work for this study showing that iodine in pregnancy was unequivocally cost saving, the aim of our analysis was to explore the robustness of this indication by solely focusing on the worst case possible.
The monetary value of an IQ point used was also intentionally conservative and excluded voluntary work and any earnings that happen after the UK retirement age. These factors potentially act to underestimate the true monetary value associated with an additional IQ Panel 1: Model assumptions relating to the women • Women take daily iodine tablets 13 weeks before pregnancy, throughout pregnancy, and for an additional 26 weeks while breastfeeding. Cessation of iodine tablets occurs at the end of the lactation period or if there is a pregnancy loss event. • Iodine supplementation will only benefi t women who were iodine defi cient before supplementation. • All iodine-defi cient women will be iodine replete with supplementation and they adhere to taking the daily supplementation. • IQ gains will be diff erent depending on the severity of iodine defi ciency before supplementation; the presupplementation iodine-defi cient women were subclassifi ed into severe and mild or moderate iodine-defi cient categories (table 1). • All pregnancies are singleton.
Panel 2: Model assumptions relating to the pregnancy losses and complications
• Women with early pregnancy losses take daily tablets for 23 weeks on average and women with late pregnancy loss take tablets for 47 weeks on average (these both include the 13 weeks of taking the iodine tablets before pregnancy). • 0·25% 25 • An increased incidence of pregnancy losses and complications for each type of thyroid dysfunction is caused by iodine supplementation. Only pregnancy complications incurring signifi cant costs (pre-eclampsia, preterm birth before 37 completed weeks of gestation, and stillbirth loss after 24 completed weeks of gestation) are used in the model. • Although pre-eclampsia and preterm births often occur together, they are separate events in the model. • The infants whose mothers had overt and subclinical hypothyroidism during pregnancy have losses of cognition of 7 IQ points. 26 On the basis of equivalent neurodevelopmental test scores, 27 this loss is also assumed for infants whose mothers had isolated hypothyroxinaemia during pregnancy. This assumption relates to the hypothyroidism that is induced by iodine supplementation in a few women and in this case is not related to iodine defi ciency. • Children of women with adverse thyroid dysfunction who had iodine supplementation and were iodine defi cient before supplementation did not have an increase in IQ after supplementation.
point. The IQ earnings premium used in the model is based on an estimate from a US study 48 in which earnings came from the years 1974 and 1990. In today's technologically driven high skill economy, the earnings benefi t from an additional IQ point might be more valuable for a worker than in previous decades. Health and public sector costs relating to childhood neurological impairment were taken from a study 41 that recorded incremental costs during a 1 year period in midchildhood (aged 11 years). The model assumed that these annual costs are the same for each year of childhood when in reality they are very likely to vary. Exclusion of these costs in the societal perspective sensitivity analysis did not change the direction of the results. No account has been made of public sector savings resulting from IQ improvement at the upper end of the IQ scale.
For the present value of lifetime earnings, a real wage growth of 1% per year in the future was assumed. 47 However, the sensitivity analysis also took into account a zero real wage growth scenario. This scenario did not prevent the iodine supplementation intervention from remaining cost saving.
This study has several limitations. First, one argument is that if most of the IQ gains will provide an absolute shift in the population IQ distribution, the relative IQ diff erences remain largely unchanged, negating most of the earnings advantages stemming from the gains in IQ points for workers. A possible response to this is that, generally, economies compete at a worldwide level and the addition of a more intelligent workforce in the future should help with productivity-linked earning gains. Second, some women might already take supplementation, which would mean that the overall modelled benefi ts might be overstated, but the analysis sought to identify the benefi ts of iodine supplementation to an individual compared with no supplementation.
We also used the sensitivity analysis to measure a person's willingness to pay for an additional IQ point instead of the monetary value of an IQ point derived from earnings. This analysis was done to allay any issues about using earnings as a basis for the value of an IQ point. However, when the monetary value of an IQ point is excluded (NHS perspective), the result showed that iodine supplementation was still cost saving.
A further possible weakness of our analysis is that iodine status is not identifi ed at the individual level for the pregnant woman and, therefore, some wastage occurs when iodine-suffi cient women receive unnecessary supplementation. However, iodine supplementation for iodine-replete pregnant women with normal thyroid function is not likely to cause any harm in most pregnancies. Despite our assumptions of harm in our model, no evidence thus far suggests that iodine supplementation induces thyroid dysfunction in pregnancy. Moreover, iodine is included in some proprietary pregnancy supplements. However, some evidence 25 of induction of thyroid dysfunction in the nonpregnant population does exist. Severe iodine defi ciency has been associated with increases in pregnancy loss and complications; rectifi cation of the iodine status of mildly to moderately iodine-defi cient women is likely to decrease rather than increase pregnancy loss, although no studies have investigated this thus far. At present, no acceptable test for the assessment of individual iodine status exists; tests for assessment of population iodine status are available, but they require collection of urine from a large sample size, which is both cumbersome and costly. Furthermore, the testing needed for a targeted programme also causes delay, whereas the evidence suggests 45 that the benefi ts of iodine supplementation are increased with earlier treatment.
The limitations in our analysis relate to the limitations in the evidence. Although the evidence for the benefi t of iodine supplementation in populations who are severely iodine defi cient is clear, 1,2 the evidence of benefi t in mildly iodine-defi cient populations has not been established. 3 Two of the three prospective studies 45, 46 of iodine supplementation in women from mildly iodine-defi cient areas have shown improvements in child cognition, but these are limited by not being randomised studies, risk of bias, and small sample sizes. A large cohort study, with a short follow-up, provides evidence of potential harm. 6 Maternal consumption of 150 μg per day or more of iodine from supplements was related to a 1·7 (95% CI 0·9-3·0) times higher risk of a child's mental scale score being less than 85 (derived from the Bayley Scales of Infant Development test), but this was not statistically signifi cant. This study was not included in the model because the association was not statistically signifi cant, the assessments were done at the age of 16 months, which is less robust than the later ages used in Bath and Hynes' study, and a third of the population used iodised salt. We based the IQ gains on an observational study, which was a cohort study comprising highly educated older women, 5 which was a major limitation, but is the most robust information available in the absence of high quality experimental evidence. Although systematic reviews exist, 2,3,55,56 none of them provides an IQ change in a mildly iodine-defi cient non-supplemented population. The use of diff erent IQ tests across studies raises the question of the comparability of fi ndings. Bath and colleagues 5 used the abbreviated form of the Wechsler Intelligence Scale for Children. Our base case estimate, taken from the study by Zax and Rees, 48 used the Henmon-Nelson Test of Mental Ability. Because these two intelligence tests are not perfectly correlated, an individual might get a slightly diff erent IQ score from each test. We explored this possibility in the sensitivity analysis by modifi cation of IQ gains and the results remained cost saving with one exception, which was based on an extreme scenario.
In the absence of randomised controlled trial evidence, our model results strengthen the case for universal iodine supplementation pre-conception and during pregnancy and lactation in mildly to moderately iodinedefi cient populations. In our study, we only took into account iodine supplementation in tablet form. Fortifi cation of food with iodine is another way of attaining iodine suffi ciency; however, food fortifi cation alone might not be enough to achieve iodine suffi ciency for pregnant women. 57 Our fi ndings have important implications worldwide. 32 countries have mild or moderate iodine defi ciency identifi ed from surveys of the iodine status of school-age children. 58 These countries have a population of 1·88 billion people and 241 million school-age children, so the potential eff ects of introduction of iodine supplementation for pregnant women could be substantial. The use of urinary iodine of school-age children to estimate the iodine status of pregnant women is likely to underestimate the prevalence of iodine defi ciency during pregnancy. 59, 60 Reduced urinary iodine concentrations have been identifi ed in pregnant women compared with school aged children, possibly because of an increased consumption of milk in children. 59 Additionally, pregnant women have an increased iodine requirement. 61 A randomised controlled trial would provide the most robust evidence on which to base policy; however, such a study would need costly child developmental assessments. A randomised controlled trial with iodinedefi cient pregnant women taking placebo iodine tablets has been described as unethical 9 because iodine supplementation in pregnancy is already recommended by many national and international bodies, including WHO. 8 On the basis of the best available evidence, this study emphasises the cost-eff ectiveness of an iodine supplementation strategy for pregnant women in the UK. Our fi ndings are applicable to any country which is mildly to moderately iodine defi cient, but has no universal salt or other iodisation programme.
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